Postural Orthostatic Tachycardia Syndrome Clinical Trial
Official title:
Einfluss Selektiver I(f)-Blockade Auf Orthostase-Toleranz Und Sympathikusaktivität Bei Gesunden
The study compares three treatment modalities in a human model of Postural orthostatic tachycardia syndrome (POTS): beta-blockers, I(f)-blockers, and placebo.
Elevated heart rate may lead to cardiac disease in the long-term. Therefore, drugs lowering
heart rate are useful. Beta-blockers are an established treatment modality. They not only
lower heart rate but also contractility, which might be undesirable in certain tachycardic
disorders.
Postural orthostatic tachycardia syndrome (POTS) patients complain about dizziness,
weakness, headache, lightheadedness, fatigue, nausea, and presyncope. In some patients there
is elevated heart rate even during supine rest. In POTS patients it is preferable to lower
heart rate without reducing cardiac contractility which can be achieved by using so-called
I(f)-blockers. Thus, they might be superior to beta-blockers in POTS.
In our study, we artificially generate POTS in healthy male subjects for about 48 hours. We
want to compare the cardiovascular effects and orthostatic tolerance of the following
treatments: beta-blocker, I(f)-blocker, and placebo.
Moreover, we will quantify changes in cardiovascular autonomic regulation brought about by
I(f)-blockade versus placebo.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05555771 -
Paediatric Syncope in the Emergency Department
|
N/A | |
Recruiting |
NCT05923840 -
Chemoreflex and Baroreflex Alterations Causing Postural Tachycardia Syndrome With Orthostatic Hyperpnea and Hypocapnia
|
N/A | |
Completed |
NCT05633407 -
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
|
Phase 2 | |
Completed |
NCT03930914 -
Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome
|
N/A | |
Recruiting |
NCT05741112 -
The Long COVID-19 Wearable Device Study
|
N/A | |
Recruiting |
NCT05454137 -
A Shared Medical Appointment Intervention for Quality of Life Improvement in POTS
|
N/A | |
Recruiting |
NCT05924646 -
CAlgary SAlt for POTS
|
N/A | |
Enrolling by invitation |
NCT05877534 -
Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study
|
N/A | |
Completed |
NCT01367977 -
Head Circumference Growth in Children With Ehlers-Danlos Syndrome Who Develop Dysautonomia Later in Life
|
||
Recruiting |
NCT04881318 -
Compression Garments in the Community With POTS
|
N/A | |
Recruiting |
NCT06292104 -
Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
|
||
Completed |
NCT02171988 -
Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)
|
Phase 4 | |
Completed |
NCT01563107 -
Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
|
N/A | |
Completed |
NCT01547117 -
Dietary Salt in Postural Tachycardia Syndrome
|
N/A | |
Completed |
NCT01617616 -
Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects
|
N/A | |
Active, not recruiting |
NCT02281097 -
Transdermal Vagal Stimulation for POTS
|
N/A | |
Completed |
NCT00728026 -
Autonomic Profiles in Pediatric Patients With Cyclic Vomiting Syndrome (CVS), Irritable Bowel Syndrome (IBS),Postural Orthostatic Tachycardia Syndrome (POTS), Functional Abdominal Pain (FAP) or Chronic Nausea
|
N/A | |
Recruiting |
NCT05481177 -
Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort
|
Phase 4 | |
Not yet recruiting |
NCT05914649 -
NC Testing in LC & POTS
|
N/A | |
Completed |
NCT05404672 -
Breathing Exercises With And Without Aerobic Training In Patients With Postural Orthostatic Tachycardia Syndrome
|
N/A |